Table 1.
Summary of studies on the clinical characteristics or renal progression of Asian patients with ADPKD
| Country | Subject of the study | Patients (n) | Study type | Year of publication | Reference |
| Australia | Genotype–phenotype correlation | 285 | Cross-sectional study | 1992 | 12 |
| China | Clinical manifestation | 205 | Cross-sectional study | 1995 | 13 |
| China | Clinical characteristics and disease progression | 541 | Prospective cohort study | 2014 | 14 |
| China | Genotype–phenotype correlation | 148 | Cross-sectional study | 2016 | 15 |
| China | Clinical features of inpatients with ADPKD | 168 | Retrospective study | 2018 | 16 |
| Iraq | Clinical manifestation | 30 | Cross-sectional study | 2011 | 17 |
| Japan | Renal progression | 255 | Retrospective study | 2012 | 18 |
| Japan | Genotype and renal progression | 112 | Retrospective study | 2015 | 19 |
| Japan | Renal progression and effect of tolvaptan in a Japanese subset of patients from Tolvaptan Efficacy and Safety in Management of Autosomal Dominant Polycystic Kidney Disease and Its Outcomes (TEMPO) 3:4 trial | 177 | Subgroup study of clinical trial | 2015 | 20 |
| Japan | Clinical characteristics according to Mayo classification | 296 | Retrospective study | 2019 | 21 |
| Pakistan | Clinical presentation | 56 | Cross-sectional study | 2008 | 22 |
| South Korea | Clinical characteristics | 461 | Cross-sectional study | 2015 | 23 |
| South Korea | Clinical characteristics | 364 | Prospective cohort study | 2018 | 24 |
| Taipei | Incidence of cardiovascular complications in patients with ADPKD compared with general population | 2062 | National database study | 2017 | 25 |
| Turkey | Clinical characteristics | 1139 | Cross-sectional study | 2011 | 26 |
| Turkey | Clinical characteristics and predictor of renal progression | 323 | Retrospective study | 2013 | 27 |
ADPKD, autosomal dominant polycystic kidney disease.